{"transactions":[{"id":2131699,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-10-26T16:15:45.000Z","date":"2022-10-21","kind":"sale","acquired":false,"shares":1527,"price":8.4843,"value":12955.5261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":131372,"source":{"system":"sec-edgar","filing":"0000899243-22-034264","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322034264/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-24"}},{"id":2131698,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-10-26T16:15:45.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":568,"price":9.3607,"value":5316.8776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":132899,"source":{"system":"sec-edgar","filing":"0000899243-22-034264","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322034264/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-24"}},{"id":2133031,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-10-24T18:23:48.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":1527,"price":8.4843,"value":12955.5261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":131372,"source":{"system":"sec-edgar","filing":"0000899243-22-034054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322034054/doc4.xml","form_type":"4"}},{"id":2133030,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-10-24T18:23:48.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":568,"price":9.3607,"value":5316.8776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":132899,"source":{"system":"sec-edgar","filing":"0000899243-22-034054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322034054/doc4.xml","form_type":"4"}},{"id":2203385,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-07-22T16:22:06.000Z","date":"2022-07-21","kind":"sale","acquired":false,"shares":1533,"price":5.3784,"value":8245.0872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.351 to $5.405. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":133467,"source":{"system":"sec-edgar","filing":"0000899243-22-026579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322026579/doc4.xml","form_type":"4"}},{"id":2204053,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-07-21T19:11:18.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":563,"price":5.2145,"value":2935.7635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0000899243-22-026517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322026517/doc4.xml","form_type":"4"}},{"id":2212173,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T07:30:13.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":26000,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000899243-22-025232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322025232/doc4.xml","form_type":"4"}},{"id":2212172,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-07-06T07:30:13.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":135563,"source":{"system":"sec-edgar","filing":"0000899243-22-025232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322025232/doc4.xml","form_type":"4"}},{"id":2291894,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-22T08:23:31.000Z","date":"2022-04-21","kind":"sale","acquired":false,"shares":1587,"price":5.8605,"value":9300.6135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.78 to $5.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":121563,"source":{"system":"sec-edgar","filing":"0000899243-22-015392","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322015392/doc4.xml","form_type":"4"}},{"id":2291893,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-22T08:23:31.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":453,"price":6.6843,"value":3027.9879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":123150,"source":{"system":"sec-edgar","filing":"0000899243-22-015392","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322015392/doc4.xml","form_type":"4"}},{"id":2308681,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T16:24:34.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":56744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":56744,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":56744},"source":{"system":"sec-edgar","filing":"0000899243-22-013336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322013336/doc4.xml","form_type":"4"}},{"id":2308680,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-04-04T16:24:34.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":23256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":123603,"source":{"system":"sec-edgar","filing":"0000899243-22-013336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322013336/doc4.xml","form_type":"4"}},{"id":2425318,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-26T16:15:28.000Z","date":"2022-01-25","kind":"sale","acquired":false,"shares":4639,"price":8.2448,"value":38247.6272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.10 to $8.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":100347,"source":{"system":"sec-edgar","filing":"0000899243-22-003264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924322003264/doc4.xml","form_type":"4"}},{"id":2535624,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-25T16:12:44.000Z","date":"2021-10-21","kind":"sale","acquired":false,"shares":1514,"price":24.2341,"value":36690.4274,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":104986,"source":{"system":"sec-edgar","filing":"0000899243-21-041423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924321041423/doc4.xml","form_type":"4"}},{"id":2900955,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T19:29:01.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-21-002768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924321002768/doc4.xml","form_type":"4"}},{"id":2900954,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-21T19:29:01.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":106500,"source":{"system":"sec-edgar","filing":"0000899243-21-002768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924321002768/doc4.xml","form_type":"4"}},{"id":3067811,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-08-05T21:39:30.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":3500,"price":17,"value":59500.0,"ownership":{"direct":true},"balance_after":78500,"source":{"system":"sec-edgar","filing":"0000899243-20-021575","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924320021575/doc4.xml","form_type":"4"}},{"id":3072658,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T18:35:40.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":407400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on July 20, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":407400,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":407400},"source":{"system":"sec-edgar","filing":"0000899243-20-020912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924320020912/doc4.xml","form_type":"4"}},{"id":3072657,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":122862,"kind":"person","name":"Atillasoy Ercem","position":1,"cik":"0001818802","reported_name":"Atillasoy Ercem","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-31T18:35:40.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 20, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. In the event of the Reporting Person's termination without cause or for good reason, the RSUs shall immediately vest in full."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000899243-20-020912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818802/000089924320020912/doc4.xml","form_type":"4"}}]}